Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Change Agents Corporation.AVCO · Entity 8466 | Director | February 25, 2020 | February 25, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Change Agents Corporation.
Report date February 25, 2020 · Filed February 25, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $1.52 · Expires 2020-02-25 | Direct | 80,000 |
Reported balance
After 2020-02-25 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-02-25 · Grant · Acquired 80,000 · Balance 80,000 F1: The Stock Options vest in 36 equal tranches commencing on the grant date. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $2.00 · Expires 2024-01-02 | Direct | 150,000 |
Reported balance
Holding disclosure · report date 2020-02-25 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 150,000 |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $2.75 · Expires 2023-12-31 | Direct | 50,000 |
Reported balance
Holding disclosure · report date 2020-02-25 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 50,000 |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $2.50 · Expires 2022-12-31 | Direct | 40,000 |
Reported balance
Holding disclosure · report date 2020-02-25 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 40,000 |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $1.49 · Expires 2022-04-27 | Direct | 30,000 |
Reported balance
Holding disclosure · report date 2020-02-25 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 30,000 |
| Common Stock, $.0001 par valueSEC Table I · non-derivative | Direct | 5,000,000 |
Reported balance
Holding disclosure · report date 2020-02-25 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 5,000,000 |
Filing footnotes · ownership attribution and instrument terms
F1: The Stock Options vest in 36 equal tranches commencing on the grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 25, 2020 Filed Feb 25, 2020 21:09 UTC | Change Agents Corporation. AVCO · Entity 8466 | GrantStock Option · Derivative | 80,000 | $1.52 Strike: $1.52 | $121,600.00 |
DisclosureSEC source: 0001213900-20-004739 · ownership.xml · derivative · entry 2 Lu Yancen · CIK 0001706384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock, $.0001 par value · 80,000 shares Expires 2020-02-25 F1 · security: The Stock Options vest in 36 equal tranches commencing on the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.